Skip to content Skip to footer
Viewpoints_Jacqueline Nielsen_Tahi Ahmadi

Unlocking Approval: Jacqueline Nielsen from AbbVie & Tahi Ahmadi from Genmab in a Riveting Conversation with PharmaShots

Shots:  Recently, the EMA’s CHMP adopted a positive opinion by recommending conditional marketing authorization for AbbVie and Genmab’s Tepkinly for the treatment of R/R Follicular Lymphoma  Today at PharmaShots, we have Jacqueline Nielsen, Head of Hematologic Oncology Affairs at AbbVie, and Tahi Ahmadi, EVP and CMO at Genmab, shedding light on this conditional marketing authorization…

Read more

Insights+ EMA Marketing Authorization of New Drugs in April 2024

Insights+: EMA Marketing Authorization of New Drugs in April 2024

Shots:   The EC approved 10 New Chemical Entities in April 2024, leading to treatments for patients and advances in the healthcare industry   In April 2024, the major highlighted drugs were Takeda’s Fruzaqla to treat Adults with mCRC and Johnson & Johnson’s Rybrevant for the treatment NSCLC  PharmaShots has compiled a list of 5 drugs that have received positive…

Read more